Non-Hodgkin Lymphoma

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1) HSE (4)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
FDA (1) HSE (2)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine
EMA (1) FDA (1) HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
FDA (1)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab
FDA (2)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
EMA (1)	CD20 +	Non-Hodgkin Lymphoma	Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Carboplatin, Etoposide, Ifosfamide, Rituximab
HSE (2)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vinorelbine
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Gemcitabine, Oxaliplatin, Rituximab
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine